Results 31 to 40 of about 21,338 (184)

Measurement of coverage, compliance and determinants of uptake in a publicly funded rotavirus vaccination programme: a retrospective cohort study

BMJ Open, 2019
Objectives In June 2015, Alberta, Canada instituted a universal publicly funded rotavirus vaccination programme (Rotarix, RV1), with vaccine doses scheduled for 2 and 4 months of age.
Lawrence W Svenson, Ellen Rafferty, Xiaoyan Guo, Bruce McDonald, Shannon Elizabeth MacDonald   +4 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008–16: findings from the Global Rotavirus Surveillance Network

The Lancet Global Health, 2019
Summary: Background: Rotavirus vaccine use in national immunisation programmes has led to declines in hospital admissions for rotavirus gastroenteritis among children; however, the global impact of rotavirus vaccine introduction has not been described ...
Negar Aliabadi, MD, Sébastien Antoni, MPH, Jason M Mwenda, PhD, Goitom Weldegebriel, MD, Joseph N M Biey, MD, Dah Cheikh, MD, Kamal Fahmy, MD, Nadia Teleb, MD, Hossam Abdelrahman Ashmony, BSc, Hinda Ahmed, PhD, Danni S Daniels, MS, Dovile Videbaek, MD, Annemarie Wasley, ScD, Simarjit Singh, MSc(IT), Lucia Helena de Oliveira, PhD, Gloria Rey-Benito, MSc, N Jennifer Sanwogou, MPH, Pushpa Ranjan Wijesinghe, MD, Jayantha B L Liyanage, MD, Batmunkh Nyambat, MD, Varja Grabovac, MSc, James D Heffelfinger, MD, Kimberley Fox, MD, Fem Julia Paladin, PhD, Tomoka Nakamura, MSPH, Mary Agócs, MD, Jillian Murray, MSPH, Thomas Cherian, MD, Catherine Yen, MD, Umesh D Parashar, MBBS, Fatima Serhan, PhD, Jacqueline E Tate, PhD, Adam L Cohen, MD   +32 more
doaj   +1 more source

Characterization of the Immune Response after Oral Cholera Vaccination (OCV) and Effects of Mycophenolate Mofetil on Priming of this Immune Response—A Randomized, Placebo‐Controlled Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used by solid organ transplant recipients. Although it is known that MMF suppresses immune responses, its exact effects on specific vaccinations have not been investigated yet. Mucosal vaccinations are increasingly used, such as a cholera vaccination consisting of two oral immunizations ...
Boukje C. Eveleens Maarse, Aliede E. in 't Veld, Hendrika W. Grievink, Manon A.A. Jansen, Matthijs Moerland   +4 more
wiley   +1 more source

PROTECTIVE ACTIVITY STUDY OF A CANDIDATE VACCINE AGAINST ROTAVIRUS INFECTION BASED ON RECOMBINANT PROTEIN FliCVP6VP8

Медицинская иммунология, 2016
Rotavirus infection is among leading causes of severe diarrhea which often leads to severe dehydration, especially, in children under 5 years old. In Russia, the incidence of rotavirus infection is constantly increased, due to higher rates of actual ...
I. V. Dukhovlinov, E. G. Bogomolova, E. A. Fedorova, A. S. Simbirtsev   +3 more
doaj   +1 more source

Rotavirus vaccines: an overview [PDF]

Clinical Microbiology Reviews, 1996
Rotavirus vaccine development has focused on the delivery of live attenuated rotavirus strains by the oral route. The initial "Jennerian" approach involving bovine (RIT4237, WC3) or rhesus (RRV) rotavirus vaccine candidates showed that these vaccines were safe, well tolerated, and immunogenic but induced highly variable rates of protection against ...
K, Midthun, A Z, Kapikian
openaire   +2 more sources

Trends in hospitalizations for vaccine‐preventable diseases in the United States from 2014 to 2024

Journal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Vaccination rates have declined in recent years, resulting in outbreaks of vaccine‐preventable diseases (VPDs) among children. We aimed to evaluate VPD hospitalization rates from 2014 to 2024 and to report associated trends in outcomes including intensive care utilization, mortality, readmissions, and costs.
Nathan M. Money, Erin Sullivan, Hannah Rector, Corrie E. McDaniel, Jessica L. Markham, Mersine A. Bryan   +5 more
wiley   +1 more source

Cost-effectiveness analysis of diarrhoea management approaches in Nigeria: A decision analytical model.

PLoS Neglected Tropical Diseases, 2017
BackgroundDiarrhoea is a leading cause of death in Nigerian children under 5 years. Implementing the most cost-effective approach to diarrhoea management in Nigeria will help optimize health care resources allocation.
Charles E Okafor, Obinna I Ekwunife
doaj   +1 more source

The impact of publicly funded rotavirus immunization programs on Canadian children

Canada Communicable Disease Report, 2021
Background: In 2008, the National Advisory Committee on Immunization recommended routine rotavirus immunizations in healthy Canadian infants. Over the following seven years, eight provinces and two territories introduced the rotavirus vaccine into their ...
Pia K Muchaal, Matt Hurst, Shalini Desai
doaj   +1 more source

Clinical progress note: Rotavirus

Journal of Hospital Medicine, EarlyView.
Abstract Rotavirus is a vaccine‐preventable cause of acute, viral gastroenteritis typically characterized by diarrhea, vomiting, and fever. Prior to rotavirus vaccine introduction, nearly all children worldwide had been infected by 5 years of age. Severe rotavirus gastroenteritis causes dehydration and electrolyte derangements, and infants and young ...
Kelsey Thetford, Meghan Hofto
wiley   +1 more source